As published on causaly.com, June 2026. Captured by usedby on Oct 8, 2026.
What happened
Manas AI uses Causaly as its primary platform for target identification and validation in drug discovery, running evidence assessments across human genetics, preclinical, clinical, competitor and safety data before committing resources to a target. It also uses the platform as a sanity check at later pipeline stages.
Summary written by usedby from the source page, in English. The figures are those of Causaly and Manas AI, not ours.
Manas AI uses Causaly as its primary platform for target identification and validation. When a candidate target is identified, whether starting from a disease pathway or from a protein family with known druggability, the team uses Causaly to run a comprehensive evidence assessment before committing resources.
Companies live and die based on the identification and veracity of their targets. If you make a mistake at the very first step, every step that follows will be a snowball effect from that initial wrong decision.
What the story claims, and what we checked
We compared the story with its live page on Oct 8, 2026.
- The passage quoted aboveCheckedCopied word for word from the page, near the name of Manas AI.
- The publication dateCheckedRead from the page’s own metadata, never guessed.
- Manas AI uses CausalyCheckedConfirmed line. Latest check across sources: Oct 8, 2026.
- The result itselfNot checkedWe quote it; we did not measure it.